Therefore, accurate detection of the tau load of living patients is useful not only for establishing AD diagnosis and selecting the patient for targeted therapy (Fleisher et al., 2020) but also for predicting a patient’s potential for clinical progression. The gene discussed is MAPT; the disease is Alzheimer disease.